Last reviewed · How we verify
Fluoropyrimidine plus leucovorin
Inhibits thymidylate synthase
Inhibits thymidylate synthase Used for Colorectal cancer, Breast cancer, Stomach cancer.
At a glance
| Generic name | Fluoropyrimidine plus leucovorin |
|---|---|
| Also known as | Xeloda |
| Sponsor | Seattle Project Corporation |
| Drug class | Antineoplastic agent |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Fluoropyrimidines, such as 5-fluorouracil, work by inhibiting thymidylate synthase, an enzyme involved in DNA synthesis. Leucovorin, also known as folinic acid, is a form of folic acid that helps to stabilize the enzyme and increase the effectiveness of the fluoropyrimidine.
Approved indications
- Colorectal cancer
- Breast cancer
- Stomach cancer
Common side effects
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer (PHASE2)
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (PHASE2)
- Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer (PHASE3)
- mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma (PHASE3)
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (PHASE1, PHASE2)
- Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma (PHASE2)
- Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluoropyrimidine plus leucovorin CI brief — competitive landscape report
- Fluoropyrimidine plus leucovorin updates RSS · CI watch RSS
- Seattle Project Corporation portfolio CI